Compare Novavax Inc (NVAX) vs Texas Instruments Incorporated (TXN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Texas Instruments Incorporated — how do they compare? Novavax Inc trades at $8.17 (market cap $1.31B), while Texas Instruments Incorporated trades at $278.59 (market cap $252.60B). The key difference: Texas Instruments Incorporated is far larger — about 192.8× Novavax Inc's market cap, and Texas Instruments Incorporated pays a 2.05% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | TXN | |
|---|---|---|
Market Cap | $1.31B | $252.60B |
Sector | Health | Technology |
52-Week High | $11.19 | $332.35 |
52-Week Low | $6.22 | $153.33 |
Enterprise Value | $890.95M | $259.65B |
Dividend Yield | — | 2.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
Texas Instruments (TXN) trades at $281.24, up 0.29% on the day, with a neutral technical signal. The company reported mixed quarterly earnings, missing in Q4 2025 but beating in Q1 and Q2 2026. Revenue for 2025 was $17.68 billion with a net income margin of 31.11%. Analyst consensus is a Buy with a $334.75 price target. Recent news highlights a CFO transition and strong AI-driven demand in data centers.
The outlook for TXN is positive, driven by AI infrastructure demand and operational leverage, but risks include high valuation multiples and increasing debt levels. Upside potential exists if the company meets Q3 2026 earnings expectations and capitalizes on analog chip growth in power management for AI and EVs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Texas Instruments Incorporated
Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.
Read more on TXN →
